All lobbying filings

Capitol Counsel LLC

Capitol Counsel LLC filed a Q3 report for Alnylam Pharmaceuticals, Inc. on October 15, 2026, reporting $30,000 in lobbying income.

Lobbying for Alnylam Pharmaceuticals, Inc. · Pharmaceutical manufacturer.

As filed: CAPITOL COUNSEL LLC for ALNYLAM PHARMACEUTICALS, INC.

All filings by Capitol Counsel LLC · Everything Alnylam Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 15, 2026

Income

$30,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medical/Disease Research/Clinical Labs

Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. PDUFA reauthorization, Clinical Trial / IND reform.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.